Your browser doesn't support javascript.
loading
International Recommendations on Postoperative Management for Potentially Resectable Locally Recurrent Nasopharyngeal Carcinoma.
Li, Ji-Shi; Blanchard, Pierre; Wong, Charlene H L; Ahn, Yong Chan; Bonomo, Pierluigi; Bresson, Damien; Caudell, Jimmy; Chen, Ming-Yuan; Chow, Velda L Y; Chua, Melvin L K; Corry, June; Dupin, Charles; Giralt, Jordi; Hu, Chao-Su; Kwong, Dora L W; Le, Quynh-Thu; Lee, Anne W M; Lee, Nancy Y; Li, You-Zhong; Lim, Chwee Ming; Lin, Jin-Ching; Mendenhall, William M; Moya-Plana, A; O'Sullivan, Brian; Ozyar, Enis; Pan, Jian-Ji; Qiu, Qian-Hui; Sher, David J; Snyderman, Carl H; Tao, Yun-Gan; Tsang, Raymond K; Wang, Xiao-Shen; Wu, Ping-An; Yom, Sue S; Ng, Wai Tong.
Afiliación
  • Li JS; Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
  • Blanchard P; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Wong CHL; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Ahn YC; Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Bonomo P; Radiation Oncology, Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.
  • Bresson D; Department of Neurosurgery, Hôpital Foch, Suresnes, France.
  • Caudell J; Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida.
  • Chen MY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Chow VLY; Division of Head and Neck Surgery, Department of Surgery, The University of Hong Kong, Hong Kong, China.
  • Chua MLK; Department of Head and Neck and Thoracic Radiation Oncology; Precision Radiotherapeutics Oncology Programme, Division of Medical Sciences, National Cancer Centre Singapore; Oncology Academic Clinical Programme, Duke-NUS Medical School, Singapore.
  • Corry J; Division of Radiation Oncology, GenesisCare Radiation Oncology, St. Vincent's Hospital, Melbourne, Victoria, Australia.
  • Dupin C; Department of Radiation Oncology, Bordeaux University Hospital, Bordeaux, France.
  • Giralt J; Department of Radiation Oncology, Vall D'Hebron University Hospital, Barcelona, Spain.
  • Hu CS; Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Fudan University Cancer Hospital, Shanghai, China.
  • Kwong DLW; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
  • Le QT; Department of Radiation Oncology, Stanford University, Stanford, California.
  • Lee AWM; Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
  • Lee NY; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York.
  • Li YZ; The Second Xiangya Hospital of Central South University, Department of Otorhinolaryngology, Head and Neck Surgery, Changsha, China.
  • Lim CM; Department of Otolaryngology-Head and Neck Surgery, Singapore General Hospital, Singapore.
  • Lin JC; Department of Radiation Oncology, Changhua Christian Hospital, Changhua, Taiwan.
  • Mendenhall WM; Department of Radiation Oncology, University of Florida, Gainesville, Florida.
  • Moya-Plana A; Department of Head and Neck Oncology, Gustave Roussy, Villejuif, France.
  • O'Sullivan B; Department of Radiation Oncology, Department of Otolaryngology-Head and Neck Surgery, Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada.
  • Ozyar E; Acibadem MAA University, School of Medicine, Department of Radiation Oncology, Istanbul, Turkey.
  • Pan JJ; Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, China.
  • Qiu QH; Department of Otolaryngology, Guangdong General Hospital, Guangdong Academy of Medical Science, Guangzhou, China.
  • Sher DJ; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas.
  • Snyderman CH; Department of Otolaryngology, University of Pittsburgh School of Medicine, Pittsburgh.
  • Tao YG; Department of Radiation Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Tsang RK; Department of Otolaryngology - Head and Neck Surgery, National University of Singapore, Singapore.
  • Wang XS; Department of Radiation Oncology, Eye & ENT Hospital, Fudan University, Shanghai, China.
  • Wu PA; Department of Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China.
  • Yom SS; Department of Radiation Oncology, University of California San Francisco, San Francisco, California.
  • Ng WT; Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, Li Ka Sh
Article en En | MEDLINE | ID: mdl-39009321
ABSTRACT
Locally recurrent nasopharyngeal carcinoma (NPC) presents substantial challenges in clinical management. Although postoperative re-irradiation (re-RT) has been acknowledged as a potential treatment option, standardized guidelines and consensus regarding the use of re-RT in this context are lacking. This article provides a comprehensive review and summary of international recommendations on postoperative management for potentially resectable locally recurrent NPC, with a special focus on postoperative re-RT. A thorough search was conducted to identify relevant studies on postoperative re-RT for locally recurrent NPC. Controversial issues, including resectability criteria, margin assessment, indications for postoperative re-RT, and the optimal dose and method of re-RT, were addressed through a Delphi consensus process. The consensus recommendations emphasize the need for a clearer and broader definition of resectability, highlighting the importance of achieving clear surgical margins, preferably through an en bloc approach with frozen section margin assessment. Furthermore, these guidelines suggest considering re-RT for patients with positive or close margins. Optimal postoperative re-RT doses typically range around 60 Gy, and hyperfractionation has shown promise in reducing toxicity. These guidelines aim to assist clinicians in making evidence-based decisions and improving patient outcomes in the management of potentially resectable locally recurrent NPC. By addressing key areas of controversy and providing recommendations on resectability, margin assessment, and re-RT parameters, these guidelines serve as a valuable resource for clinical experts involved in the treatment of locally recurrent NPC.

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Int J Radiat Oncol Biol Phys Año: 2024 Tipo del documento: Article País de afiliación: China